Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 5186

Original article / research
Table of Contents - Year : 2017 | Month : April | Volume : 11 | Issue : 4 | Page : OC14 - OC16

Effect of Ranolazine in Patients with Chest Pain and Normal Coronaries- A Hospital Based Study OC14-OC16

Swapan Saha, Tony Ete, Manish Kapoor, Pravin Kumar Jha, Rinchin Dorjee Megeji, Gaurav Kavi, Synrang Batngen Warjri, Animesh Mishra

Correspondence
Dr. Tony Ete,
Senior Resident, Department of Cardiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences,
Mawdiangdiang, Shillong-793018, Meghalaya, India.
E-mail: tonyete14@gmail.com

Introduction: There is an important role of coronary microcirculation in the clinical presentation and prognosis of patients who have typical chest pain despite normal epicardial coronary arteries (microvascular angina). Treatment of these patients is empirical because of the incomplete knowledge of its cause. Limited data has shown that ranolazine reduces angina and improves exercise performance in such patients with frequent angina.

Aim: To evaluate the effect of ranolazine in patients with chest pain and normal epicardial coronaries (micro-vascular angina).

Materials and Methods: Sixty-five patients with anginal symptoms with abnormal exercise stress test and normal epicardial coronaries were enrolled for the study. All participants had baseline demographic and health history questionnaires, including Seattle Angina Questionnaire (SAQ) and Duke Activity Status Index (DASI). After enrolment, patients were randomly divided into two groups. One group (group 1) was assigned to ranolazine for six weeks along with other indicated anti-anginal drugs. The other group (group 2) was assigned to anti-anginal drugs other than ranolazine. Patients were reassessed for symptomatic and functional improvement (SAQ, DASI) at six weeks.

Results: Mean age of patients examined were 49.03 years in group 1 and 49.77 years in group 2. Approximately 42.9% of patients in group 1 and 40% in group 2 were male. Despite current anti-anginal therapy, patients in both the groups were symptomatic. At six weeks, 60% of patients in group 1 had angina as compared to 88.6% at baseline (p<0.05). Similarly, scores of domains of SAQ were higher at six weeks as compared to baseline (p<0.05) except for treatment satisfaction. No improvement of DASI score and functional capacity were seen in either group at six weeks as compared to baseline (p>0.05). At six weeks, angina was significantly lower in group 1 as compared to group 2 (60 % vs 86.7%; p<0.05). Four out of five SAQ subscale score were higher in ranolazine group as compared to the other group (p<0.05). Treatment satisfaction trended lower on ranolazine group (p<0.05). There was no significant differences in DASI in the two groups (DASI score 30.59 vs 29.85, p>0.05).

Conclusion: Ranolazine is safe and improves symptoms significantly in patients with micro-vascular angina.